Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Haywood at 7.4 millions stock.

<< Previous

Bullboard Posts

Next >>

Comment by Francine01on May 10, 2019 10:04am

31 Views

Post# 29733705

RE:RE:RE:RE:Haywood at 7.4 millions stock.

lololol boozy boozy stop saying stupid and false comments. Its all fasle.

Haywood its its below the 10% with 7,400,000 shares and have 2,300,000 warrants. He didn't sell is position for only the warrant.

https://www.sec.gov/Archives/edgar/data/1000514/000114420419007131/tv513512_sc13ga.htm

Like every long term investors (like me) we all have warrants. Stop saying stupid and false comments . :)

<< Previous

Bullboard Posts

Next >>

Gold opportunity in Australia’s Northern Territory shines bright